Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis: A randomized trial
Abstract
Abstract Objective: To compare the efficacy and safety of ondansetron versus metoclopramide in the treatment of vomiting for acute gastroenteritis in the prehospital setting. Study design: This was a double-blind trial including consecutive patients aged between 1-14 years treated in an urban urgent care setting. A total of 167 children were randomized to receive a single dose of intravenous ondansetron or metoclopramide. The primary efficacy outcome was the proportion of patients with cessation of vomiting right after completion of the study medication infusion in each group. Observed side effects, diarrhea frequency in admission and follow up were recorded to assess safety. Results: A total of 167 previously healthy children (median age, 3 years) diagnosed with acute gastroenteritis with persistent vomiting completed treatment and observation. Cessation of vomiting was achieved in 68/84 patients (81%) of the ondansetron, and 60/83 (72%) of the metoclopramide groups, P=0.14. Mean time to complete cessation of vomiting was 39 min (SD111) for ondansetron, and 61 min (SD110) for metoclopramide groups, P= 0.2. The mean length of hospital stay was 550 min (SD 427) for ondansetron, and 575 min (SD 449) for metoclopramide groups, P=0.71. Revisits rate, readmissions rate and frequency of diarrhea after discharge were similar in the 2 treatment groups. No adverse reaction or other safety concerns were identified. Conclusions: Intravenous metoclopramide is effective and might be…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 167 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.